Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 2
1969 2
1970 1
1971 2
1972 2
1973 2
1974 1
1975 14
1976 27
1977 29
1978 36
1979 32
1980 28
1981 34
1982 40
1983 50
1984 48
1985 75
1986 68
1987 64
1988 73
1989 94
1990 83
1991 84
1992 99
1993 84
1994 109
1995 126
1996 124
1997 125
1998 114
1999 125
2000 120
2001 106
2002 111
2003 123
2004 146
2005 173
2006 154
2007 153
2008 168
2009 182
2010 197
2011 210
2012 240
2013 237
2014 241
2015 279
2016 224
2017 225
2018 226
2019 209
2020 245
2021 212
2022 186
2023 146
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

5,759 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
How effective is 5-Fluorouracil as an adjuvant in the management of odontogenic keratocyst? A systematic review and meta-analysis.
Singh AK, Khanal N, Chaulagain R, Bhujel N, Singh RP. Singh AK, et al. Br J Oral Maxillofac Surg. 2022 Jul;60(6):746-754. doi: 10.1016/j.bjoms.2022.02.001. Epub 2022 Feb 17. Br J Oral Maxillofac Surg. 2022. PMID: 35314081 Review.
This has generated interest in exploring alternative chemical agents such as 5-Fluorouracil (5-FU) and Modified Carnoy's solution (MCS). We conducted a systematic review and meta-analysis to assess the effectiveness of 5-FU as an adjunct following surgical intervention of …
This has generated interest in exploring alternative chemical agents such as 5-Fluorouracil (5-FU) and Modified Carnoy's solution (MC …
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Conroy T, et al. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Lancet Oncol. 2014. PMID: 24556041 Clinical Trial.
The PRODIGE5/ACCORD17 trial aimed to assess the efficacy and safety of the FOLFOX treatment regimen (fluorouracil plus leucovorin and oxaliplatin) versus fluorouracil and cisplatin as part of chemoradiotherapy in patients with localised oesophageal cancer. ...Patien …
The PRODIGE5/ACCORD17 trial aimed to assess the efficacy and safety of the FOLFOX treatment regimen (fluorouracil plus leucovorin and …
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Cassidy J, et al. J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898. J Clin Oncol. 2008. PMID: 18421053 Clinical Trial.
PURPOSE: To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC). ...
PURPOSE: To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOL …
[Fluorouracil implants for colorectal cancer: a systematic review and meta-analysis].
Huang Y, Nie YL, Zhang MM, Li YL, Chen JR. Huang Y, et al. Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Apr;15(4):377-81. Zhonghua Wei Chang Wai Ke Za Zhi. 2012. PMID: 22539386 Review. Chinese.
OBJECTIVE: To evaluate the benefit and safety of fluorouracil implants on colorectal cancer. METHODS: Based on the methods of Cochrane systematic reviews, databases including CBM(1982 to March 2011), CNKI(1911 to March 2011), EMBASE(1966 to March 2011), and Medline(1950 to …
OBJECTIVE: To evaluate the benefit and safety of fluorouracil implants on colorectal cancer. METHODS: Based on the methods of Cochran …
Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z, Deng Y. Wu Z, et al. Curr Treat Options Oncol. 2018 Nov 27;19(12):77. doi: 10.1007/s11864-018-0597-y. Curr Treat Options Oncol. 2018. PMID: 30483908 Review.
Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs. 5-FU can be administered through a bolus injection or continuous i …
Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metast …
RETRACTED: Comparison between diagnostic performance of intestinal Fusobacterium nucleatum, Bacteroides fragilis and Escherichia coli in 5-fluorouracil resistance to colorectal cancer: A meta-analysis.
Wang WY, Zhou H, Wang Z, Zhang YH. Wang WY, et al. Cancer Treat Res Commun. 2022;32:100536. doi: 10.1016/j.ctarc.2022.100536. Epub 2022 Feb 22. Cancer Treat Res Commun. 2022. PMID: 35567912 Free article. Retracted. Review.
The reasons include that the results are not comparable to the diagnostic performance of three bacteria species in 5-fluorouracil resistance in CRC from the clinical studies which are conducted to detect each type of bacteria separately. ...
The reasons include that the results are not comparable to the diagnostic performance of three bacteria species in 5-fluorouracil res …
Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis.
Chen XD, He FQ, Chen M, Tang LC, Tang XL. Chen XD, et al. Medicine (Baltimore). 2016 Jun;95(24):e3916. doi: 10.1097/MD.0000000000003916. Medicine (Baltimore). 2016. PMID: 27310997 Free PMC article. Review.
It remains to be seen whether S-1 can be a replacement for infusional fluorouracil (5-FU) for advanced gastric cancer (AGC). The aim of this study was to compare the efficacy and safety of S-1 with 5-FU in AGC.PubMed and Cochrane Library were searched. ...
It remains to be seen whether S-1 can be a replacement for infusional fluorouracil (5-FU) for advanced gastric cancer (AGC). The aim …
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Bang YJ, et al. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7. Lancet. 2012. PMID: 22226517 Clinical Trial.
Randomized, vehicle-controlled trials of topical 5-fluorouracil therapy for actinic keratosis treatment: an overview.
Rahvar M, Lamel SA, Maibach HI. Rahvar M, et al. Immunotherapy. 2012 Sep;4(9):939-45. doi: 10.2217/imt.12.93. Immunotherapy. 2012. PMID: 23046237 Review.
Actinic keratoses are common in older individuals and topical immunotherapy is an important treatment when multiple lesions are present. To assess the efficacy of 5-fluorouracil in treating actinic keratoses, a systematic review of randomized, vehicle-controlled trials was …
Actinic keratoses are common in older individuals and topical immunotherapy is an important treatment when multiple lesions are present. To …
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Polk A, et al. Cancer Treat Rev. 2013 Dec;39(8):974-84. doi: 10.1016/j.ctrv.2013.03.005. Epub 2013 Apr 10. Cancer Treat Rev. 2013. PMID: 23582737 Review.
PURPOSE: To systematically review the incidence, manifestations and predisposing factors for cardiovascular toxicity in cancer patients treated with systemic 5-fluorouracil or capecitabine. DESIGN: We searched PubMed, EMBASE and Web of science for studies with 20 cancer pa …
PURPOSE: To systematically review the incidence, manifestations and predisposing factors for cardiovascular toxicity in cancer patients trea …
5,759 results